AxoGen Inc
AXGN17.260USD
+0.440+2.62%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
789.91MMarket Cap
LossP/E TTM
More Details of AxoGen Inc Company
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
Company Info
Ticker SymbolAXGN
Company nameAxoGen Inc
IPO dateDec 17, 1986
CEOMr. Michael Donald (Mike) Dale
Number of employees451
Security typeOrdinary Share
Fiscal year-endDec 17
Address13631 Progress Blvd.
CityALACHUA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code32615
Phone13864626817
Websitehttps://www.axogeninc.com/
Ticker SymbolAXGN
IPO dateDec 17, 1986
CEOMr. Michael Donald (Mike) Dale
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
151.77K
+0.91%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
21.40K
-38.73%
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
20.76K
--
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
12.68K
-54.18%
Mr. Rick Ditto
Mr. Rick Ditto
Vice President - Global Health Economics, Reimbursement & Policy
Vice President - Global Health Economics, Reimbursement & Policy
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Independent Director
Independent Director
--
--
Ms. Kathy Weiler
Ms. Kathy Weiler
Independent Director
Independent Director
--
--
Mr. Marc A. Began
Mr. Marc A. Began
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
Mr. William P. (Bill) Burke
Mr. William P. (Bill) Burke
Independent Director
Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
151.77K
+0.91%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
21.40K
-38.73%
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
20.76K
--
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
12.68K
-54.18%
Mr. Rick Ditto
Mr. Rick Ditto
Vice President - Global Health Economics, Reimbursement & Policy
Vice President - Global Health Economics, Reimbursement & Policy
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2023
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
United States
159.01M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
First Light Asset Management, LLC
9.84%
BlackRock Institutional Trust Company, N.A.
6.74%
The Vanguard Group, Inc.
5.92%
Morgan Stanley & Co. LLC
4.20%
Balyasny Asset Management LP
4.20%
Other
69.10%
Shareholders
Shareholders
Proportion
First Light Asset Management, LLC
9.84%
BlackRock Institutional Trust Company, N.A.
6.74%
The Vanguard Group, Inc.
5.92%
Morgan Stanley & Co. LLC
4.20%
Balyasny Asset Management LP
4.20%
Other
69.10%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
36.08%
Investment Advisor
26.43%
Hedge Fund
18.12%
Research Firm
5.98%
Individual Investor
4.69%
Bank and Trust
0.34%
Pension Fund
0.30%
Sovereign Wealth Fund
0.13%
Insurance Company
0.03%
Other
7.90%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
352
41.91M
91.08%
-2.35M
2025Q1
357
42.08M
92.45%
-1.70M
2024Q4
343
39.00M
87.97%
-5.62M
2024Q3
323
39.49M
90.05%
-1.54M
2024Q2
302
38.53M
87.94%
-4.16M
2024Q1
307
37.61M
87.02%
-4.05M
2023Q4
318
35.68M
82.81%
-5.15M
2023Q3
322
35.50M
82.64%
-5.39M
2023Q2
319
36.28M
84.47%
-3.01M
2023Q1
324
35.99M
84.11%
-3.05M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
First Light Asset Management, LLC
4.47M
9.82%
-32.58K
-0.72%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.13M
6.87%
+93.19K
+3.07%
Mar 31, 2025
The Vanguard Group, Inc.
2.53M
5.55%
+103.94K
+4.28%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.59M
3.48%
-105.62K
-6.24%
Mar 31, 2025
Balyasny Asset Management LP
680.19K
1.49%
+380.25K
+126.77%
Mar 31, 2025
ArrowMark Colorado Holdings, LLC
1.59M
3.49%
-657.69K
-29.25%
Mar 31, 2025
Soleus Capital Management, L.P.
1.45M
3.18%
-1.51M
-51.08%
Mar 31, 2025
Wasatch Global Investors Inc
774.63K
1.7%
+774.63K
--
Mar 31, 2025
Zaderej (Karen L)
1.14M
2.51%
+71.04K
+6.62%
Mar 21, 2024
State Street Global Advisors (US)
1.01M
2.23%
+49.10K
+5.08%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
